DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Kite Pharma
Kite Pharma
Jefferies Global Healthcare Conference June 2, 2015 Forward Looking Statements / Safe Harbor
Key Metrics for Recent Technology and Life Sciences Initial Public Offerings
Nasdaq & TSX
Investment Thesis for Kite Pharma, Inc. (Nasdaq: Kite)
Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
Axelrod V. Kite Pharma, Inc. Et
Gene Therapy to Fight a Blood Cancer Succeeds in Major Study Marilynn Marchione, Ap Chief Medical Writer Updated 2:21 Am, Thursday, March 2, 2017
For Immediate Release Pfizer Media Contact: April 3, 2018 Jessica Smith (212) 733-6213
[email protected]
Rapid Tumor Regression from PD-1 Inhibition After Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Diffuse Large B-Cell Lymphoma
Kite Pharma Initiates Phase 1B/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The Cancer Immunotherapy Pilot Program and Chimeric Antigen Receptor-T Cell Treatments
Kite Pharma and the Leukemia & Lymphoma
Kite Pharma Announces Patients with Aggressive Non-Hodgkin's
Kite a Gileau Company
Kite Pharma, Inc. (Exact Name of Registrant As Specified in Its Charter)
Kite Pharma, Inc., Appoints Jeffrey S. Wiezorek, M.D., M.S., As Vice President, Clinical Development
Kite Pharma Details KTE-C19 Launch Preparedness and Near-Term, Next Generation CAR/TCR Product Candidates at Investor Day
Kite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Pivotal Multi-Center Phase 2 Study of KTE-C19 (ZUMA-1)
Top View
TH 1040 3 Kite Pharma FINAL.Pdf
Deal of the Week: Gilead to Buy Kite for $11.9B
Advances in Aggressive Lymphoma from the 2017 American Society Of
Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle
Allogene Therapeutics Announces Board of Directors
Highlights in CAR T-Cell Therapy from the 61St American Society Of
CONFIDENTIALITY NOTICE This Document Contains Proprietary and Confidential Information of Kite Pharma Inc., a Wholly Owned Subs
Kite Pharma Announces Clinical Biomarker Results of Anti-CD19 CAR T Cell Therapy at the 57Th American Society of Hematology Annual Meeting (ASH)
Kite Pharma, Inc. Own Immune System to Selectively Attack And
Kite Pharma Announces the Appointment of Arie Belldegrun, M.D., As President and Chief Executive Officer
Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment
July 29, 2019 David a Lambertson, Ph.D. Senior Technology Transfer
Package Insert
BOB 2020 Conference Book
Kite Pharma Enhances Commercial Expertise with the Appointment of Ian T
Gilead Sciences | Kite Pharma
Kite Pharma Inc. NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY PROTOCOL
2020-2021 Annual Meeting Scientific Program Committee All Relationships Are Considered Compensated
Kite Pharma Names Christine Cassiano As Senior Vice President of Corporate Communications and Investor Relations
View the Disclosures for the 2020 Cancer Communications Committee
1 in the United States District Court for the Eastern
Daiichi Sankyo Establishes Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma
Biotech Moffitt Cancer Center2016 AGENDA
Kite Pharma Strengthens Its T Cell Receptor (TCR) Cancer Gene Therapy Platform Through Acquisition of T-Cell Factory B.V